+86 400-682-2521 | order.cn@acrobiosystems.com 注册
登录 | 注册    关注公众号 |  
微信公众号
ACRO百普赛斯_logo Recombinant Proteins iso9001 ISO13485 CNAS
热门搜索：TL1A Hot|GMP细胞因子Hot|FcRn Binding Kit (TR-FRET)New|ADC定点偶联试剂盒
ABCDEFGHIJKLMNOPQRSTUVWXYZ0-9
搜索
 > 【GP120】

GP120信息

英文名称：HIV envelope protein gp120
中文名称：HIV包膜蛋白gp120
靶点别称：HIV Envelope Protein gp120
上市药物数量：2
临床药物数量：12
最高研发阶段：批准上市

GP120产品咨询

* 此表格只用于收集产品需求咨询，所有信息将严格保密。
*
*
*
*
*
*
抗体药
 
细胞治疗
 
基因治疗
 
诊断
 
疫苗
 
化药
 
蛋白及多肽药物
 
神经科学
 
XDC
 
其他
 
ACRO质量管理体系
 
评论(0)
 

GP120分子别名

GP120,GP120-CN54

GP120分子背景

Human Immunodeficiency Virus (HIV) can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to viruses found in chimpanzees and gorillas living in western Africa. HIV-2 is related to viruses found in sooty mangabeys. HIV-1 viruses may be further divided into groups. The HIV-1 group M viruses predominate and are responsible for the AIDS pandemic. Some of the HIV-1 group M subtypes are known to be more virulent or are resistant to different medications. HIV-2 viruses are thought to be less virulent and transmissible than HIV-1 M group viruses.
Envelope glycoprotein GP120 (or gp120) is the name of the glycoprotein which forms the spikes sticking out of a HIV virus particle. gp120 is essential for virus entry into cells as it plays a vital role in seeking out specific cell surface receptors for entry. Three gp120s, bound as heterodimers to a transmembrane glycoprotein, gp41, are thought to combine in a trimer to form the envelope spike, which is involved in virus-cell attachment. One half of the molecular weight of gp120 is due to the carbohydrate side chains (the "glyco-" in "glycoprotein"). These are sugar residues which form something almost like a sugar "dome" over the gp120 spikes. This dome prevents gp120 from being recognised by the human immune response. As the HIV virus and the human CD4 cell come together, the gp120 binding site "snaps open" at the last minute.The glycoprotein gp120 is anchored to the viral membrane, or envelope, via non-covalent bonds with the transmembrane glycoprotein, gp41. It is involved in entry into cells by binding to CD4 receptors, particularly helper T-cells. Binding to CD4 is mainly electrostatic although there are van der Waals interactions and hydrogen bonds.

GP120上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Radha-108 批准上市 Biomix Network Receptol HIV感染 详情
Fostemsavir Tromethamine BMS-663068; 97IQ273H4L (UNII code); GSK 3684934; BMS-663068-03; GSK-3684934A; BMS 626529 prodrug 批准上市 百时美施贵宝 Rukobia United States HIV感染 Viiv Healthcare Co 2020-07-02 HIV感染 详情

GP120临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Zinlirvimab 10-1074; 10-1074-LS; GS-2872 临床二期 The Rockefeller University HIV感染, 获得性免疫缺损综合征 详情
PGT121.414.LS VRC-HIVMAB0107-00-AB 临床二期 National Institute Of Allergy And Infectious Diseases (Niaid) HIV感染 详情
PGT-121 PGT-121 临床二期 International Aids Vaccine Initiative, Theraclone Sciences Inc, The Scripps Research Institute Inc, The Ragon Institute Of Mgh, Mit And Harvard HIV感染, 获得性免疫缺损综合征, 逆转录病毒感染, 病毒性性传播疾病 详情
Teropavimab 3BNC117-LS-J; 3BNC117-LS; 3BNC117; GS-5423 临床二期 The Rockefeller University HIV感染, 获得性免疫缺损综合征 详情
Microbicide monoclonal antibody triple combination (Polymun Scientific Immunobiologische Forschung) 临床一期 Polymun Scientific Gmbh HIV感染 详情
PDPHV-201401 PDPHV-201401 临床一期 National Institute Of Allergy And Infectious Diseases (Niaid) HIV感染 详情
Elipovimab GS-9722 临床一期 Gilead Inc HIV感染 详情
VRC-HIVAAV070-00-GT AAV8-VRC07 临床一期 National Institute Of Allergy And Infectious Diseases (Niaid) HIV感染 详情
Microbicide Monoclonal Antibody Triple Combination (Polymun) 临床一期 HIV感染 详情
env (A, B, C, A/E)/gag DNA Vaccine(NIAID) PD-201401 临床一期 National Institute Of Allergy And Infectious Diseases (Niaid) HIV感染 详情
Vrc-Hivmab0121-00-Ab CAP256J3LS 临床一期 National Institute Of Allergy And Infectious Diseases (Niaid) HIV感染 详情
FB-1002(Frontier Biotechnologies) FB-1002(前沿生物) 临床一期 前沿生物药业（南京）股份有限公司, 中国科学院上海药物研究所 新型冠状病毒感染 详情
DS-003 DS-003; BMS-793 临床一期 百时美施贵宝 HIV感染, 肿瘤 详情
A-1801 A-1801 临床阶段不明 武汉波睿达生物科技有限公司 HIV感染 详情

扫一扫关注微信公众号获取ACRO最新资讯

ACROBiosystems百普赛斯生物科技股份有限公司

全国：+86 400-682-2521

北京：010-53681107

上海：021-50850665

海外：+1 800-810-0816

邮箱：（产品订购）order.cn@acrobiosystems.com

邮箱：（技术支持）tech.cn@acrobiosystems.com

邮箱：（廉洁合规）lianjie@acrobiosystems.com

地址：北京经济技术开发区宏达北路8号5号楼4层

新闻订阅

订阅

在线留言

发送
隐私政策 | 法律法规 | 网站地图 | 加入我们
©2017 ACROBiosystems中国 京公网安备 11030102010599号 京ICP备16032159号-1

消息提示

请输入您的联系方式,再点击提交！

确定